United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

8 Dec 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for JNJ


Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... (more)


Beta: 0.72
Market Cap(Mil.): $301,951.81
Shares Outstanding(Mil.): 2,720.53
Dividend: 0.80
Yield (%): 2.88


  JNJ Industry Sector
P/E (TTM): 19.45 29.74 30.35
EPS (TTM): 5.71 -- --
ROI: 14.16 15.90 15.27
ROE: 22.09 17.00 16.60

J&J questions fairness of hip implant trial, $1 billion verdict

Johnson & Johnson will challenge the fairness of a trial that produced a verdict of $1 billion in damages against the company last week over allegations of design flaws in its Pinnacle hip implant.

Dec 07 2016

Top Actelion shareholder says backs J&J deal above 246 Sfr/share

LONDON A top-30 investor in Swiss pharmaceutical company Actelion said he would back a takeover approach for the whole company from U.S. rival Johnson & Johnson above 246 Swiss francs.

Dec 06 2016

Trump's corporate tax holiday could spur pharma M&A

U.S. President-elect Donald Trump's plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its way into growth.

Dec 06 2016

Sanofi exploring bid for Actelion amid J&J talks: Bloomberg

French drugmaker Sanofi is considering a bid for Swiss biotech company Actelion , rivaling an offer made by U.S. healthcare company Johnson & Johnson , Bloomberg reported.

Dec 06 2016

Actelion's silence has hedge funds betting big on J&J deal

ZURICH Actelion's silence speaks volumes to the dozens of event-driven hedge funds piling into the Swiss biotech firm, betting that Johnson & Johnson's (J&J) approach will result in an outright takeover and handsome returns.

Dec 02 2016

Johnson & Johnson hit with over $1 billion verdict on hip implants

A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay more than $1 billion to six plaintiffs who said they were injured by Pinnacle hip implants.

Dec 01 2016

Actelion shares fall on report it rejects J&J offer

ZURICH Shares in Swiss biotech company Actelion fell more than 6 percent after news outlet streetinsider.com reported on Wednesday the company had rejected a full takeover offer by U.S. healthcare group Johnson & Johnson and may sell a unit.

Nov 30 2016

Rejecting J&J could leave Actelion with 'lot of explaining to do'

ZURICH/LONDON Some Actelion shareholders would be attracted by a $27 billion bid for the Swiss biotech company from Johnson & Johnson, leaving Chief Executive Jean-Paul Clozel with some explaining to do if he turned down an offer around that level.

Nov 30 2016

Deals of the day-Mergers and acquisitions

Nov 29 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Tuesday:

Nov 29 2016

J&J raises Actelion takeover pressure with higher price: source

LONDON U.S. healthcare company Johnson & Johnson has raised its offer for Actelion, a source told Reuters on Tuesday, stepping up pressure on the Swiss biotech firm to accept a takeover deal.

Nov 29 2016

Earnings vs. Estimates